NanoViricides, Inc.
3:15 PM - 3:30 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
NanoViricides, Inc. is developing highly effective & safe antivirals acting by a novel mechanism of action: “Re-Infection Blockers”, orthogonal to replication inhibitors.
NV-CoV-2 for treatment of COVID is in human Clinical Trials. It is a broad-spectrum, pan-coronavirus drug with resistance unlikely from coronavirus variants. Formulated for Oral Syrup, Oral Gummies, and Solution for Injection, Infusion and Inhalation. The nanoviricides are proven to significantly improve pharmacokinetics of encapsulated APIs (remdesivir, others). NV-CoV-2-R is expected to cure coronavirus infections, by attacking both reinfection and replication. Platform technology enabling drug candidates against many viral diseases of biodefense and public health interest: HIV, HerpesV, RSV,CoV, Other respiratory Viruses, DengueV, Ebola/MarburgV, others. Additionally, NV-HHV-1 for treatment of shingles has completed IND-enabling studies. Company has own cGMP-compliant manufacturing facility for clinical scale.
Ticker:
NNVC
Exchange:
NYSE-American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2005
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
NV-CoV-2 for COVID treatment.
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3 Products.
2 Technologies.
Speaker
